Publications by authors named "Dirk Heerwegh"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

102,851

Total Likes

6,245

Extended Reach

2,487,301

Social Features

366
V
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Jerome Custers, Denny Kim, Maarten Leyssen, Marc Gurwith, Frank Tomaka, James Robertson, Esther Heijnen, Richard Condit, Georgi Shukarev, Dirk Heerwegh

May 2021

Videos about Article: user user

2 1 21 6

View All Article and Social Media Activity
I
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels

May 2021

Videos about Article: user user user 1

4 1 9 338 22 201 5

View All Article and Social Media Activity
D
Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.
Heidi Tiller, Eleonor Tiblad, Pamela Baker, Hillary Van Valkenburgh, Dirk Heerwegh

Am J Perinatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.
Sanne Roels, Matthias Bruckner, Jerald Sadoff, Vicky Cárdenas, Chan Tang, Dirk Heerwegh

Vaccine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
Mathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, Dirk Heerwegh, Fisseha Tesfaye

Vaccine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).
Yannick Vandendijck, Jane Scott, Dirk Heerwegh, Wim Van Der Elst, James Witek

Influenza Other Respir Viruses· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson

NPJ Vaccines· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
Mathieu Le Gars, Jerald Sadoff, Frank Struyf, Dirk Heerwegh, Carla Truyers

J Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Jerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Dirk Heerwegh

Vaccine· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Muhammed O Afolabi, David Ishola, Daniela Manno, Babajide Keshinro, Viki Bockstal, Dirk Heerwegh

Lancet Infect Dis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
David Ishola, Daniela Manno, Muhammed O Afolabi, Babajide Keshinro, Viki Bockstal, Dirk Heerwegh

Lancet Infect Dis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.
Lisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Dirk Heerwegh

NPJ Vaccines· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B Sirima, Dirk Heerwegh

PLoS Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B Sirima, Dirk Heerwegh

PLoS Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Dirk Heerwegh

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Galit Alter, Jingyou Yu, Jinyan Liu, Abishek Chandrashekar, Erica N Borducchi, Dirk Heerwegh

Nature· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Dirk Heerwegh

medRxiv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Nadine C Salisch, Kathryn E Stephenson, Kristi Williams, Freek Cox, Leslie van der Fits, Dirk Heerwegh

Ann Intern Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, Anne Marit de Groot, Dirk Heerwegh

JAMA· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
Lucas Otieno, Martina Oneko, Walter Otieno, Joseph Abuodha, Emmanuel Owino, Dirk Heerwegh

Lancet Infect Dis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.
Christian F Ockenhouse, Jason Regules, Donna Tosh, Jessica Cowden, April Kathcart, Dirk Heerwegh

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis